These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24900457)

  • 1. Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
    Skerlj R; Bridger G; Zhou Y; Bourque E; McEachern E; Danthi S; Langille J; Harwig C; Veale D; Carpenter B; Ba T; Bey M; Baird I; Wilson T; Metz M; MacFarland R; Mosi R; Bodart V; Wong R; Fricker S; Huskens D; Schols D
    ACS Med Chem Lett; 2012 Mar; 3(3):216-21. PubMed ID: 24900457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
    Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
    Curr Top Med Chem; 2008; 8(13):1140-51. PubMed ID: 18782009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
    Skerlj R; Bridger G; Zhou Y; Bourque E; McEachern E; Metz M; Harwig C; Li TS; Yang W; Bogucki D; Zhu Y; Langille J; Veale D; Ba T; Bey M; Baird I; Kaller A; Krumpak M; Leitch D; Satori M; Vocadlo K; Guay D; Nan S; Yee H; Crawford J; Chen G; Wilson T; Carpenter B; Gauthier D; Macfarland R; Mosi R; Bodart V; Wong R; Fricker S; Schols D
    J Med Chem; 2013 Oct; 56(20):8049-65. PubMed ID: 24090135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
    Cumming JG; Tucker H; Oldfield J; Fielding C; Highton A; Faull A; Wild M; Brown D; Wells S; Shaw J
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1655-9. PubMed ID: 22266038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
    Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
    Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
    Cumming JG; Bower JF; Waterson D; Faull A; Poyser PJ; Turner P; McDermott B; Campbell AD; Hudson J; James M; Winter J; Wood C
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3895-9. PubMed ID: 22608963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances of CCR5 antagonists.
    Baba M
    Curr Opin HIV AIDS; 2006 Sep; 1(5):367-72. PubMed ID: 19372835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block.
    Martin RL; McDermott JS; Salmen HJ; Palmatier J; Cox BF; Gintant GA
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):369-79. PubMed ID: 15076220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
    Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
    Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HERG block, QT liability and sudden cardiac death.
    Brown AM
    Novartis Found Symp; 2005; 266():118-31; discussion 131-5, 155-8. PubMed ID: 16050265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.
    Shamovsky I; Connolly S; David L; Ivanova S; Nordén B; Springthorpe B; Urbahns K
    J Med Chem; 2008 Mar; 51(5):1162-78. PubMed ID: 18257512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
    Thomas D; Wimmer AB; Wu K; Hammerling BC; Ficker EK; Kuryshev YA; Kiehn J; Katus HA; Schoels W; Karle CA
    Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):462-72. PubMed ID: 15098086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
    Kamaura M; Kubo O; Sugimoto H; Noguchi N; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Murata T; Sato K
    Bioorg Med Chem; 2021 Mar; 34():116034. PubMed ID: 33548803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hERG channel activator, RPR260243, enhances protective
    Shi YP; Pang Z; Venkateshappa R; Gunawan M; Kemp J; Truong E; Chang C; Lin E; Shafaattalab S; Faizi S; Rayani K; Tibbits GF; Claydon VE; Claydon TW
    Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H251-H261. PubMed ID: 32559136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
    Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
    Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).
    Gerlach AC; Stoehr SJ; Castle NA
    Mol Pharmacol; 2010 Jan; 77(1):58-68. PubMed ID: 19805508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
    Xia M; Shahane SA; Huang R; Titus SA; Shum E; Zhao Y; Southall N; Zheng W; Witt KL; Tice RR; Austin CP
    Toxicol Appl Pharmacol; 2011 May; 252(3):250-8. PubMed ID: 21362439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.